Nonetheless, the contribution of GRO-α and its receptor CXCR2 to clinical features and survival of patients with pancreatic cancer remains obscure, and further studies are required for precise evaluation of the therapeutic and prognostic values of GRO-α and CXCR2 in pancreatic carcinoma. Here, CXCL1 is linked to familial pancreatic carcinoma.